HBV Replication Evaluation System and MAPK Inhibitor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating hepatitis B virus (HBV) replication are inefficient, requiring infectious virus and limited cell types, leading to low throughput and safety concerns, and existing therapeutic agents face challenges with drug resistance and recurrence of hepatitis B.
Innovation Solution
A novel evaluation system using common cells to visualize and quantify HBV DNA replication without infectious virus, combined with MAPK kinase inhibitors like Hypothemycin to inhibit HBV replication, offering a different mode of action for treating hepatitis B.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nucleotide/nucleoside analog formulations are used to treat chronic hepatitis B, then blood virus load decreases and progression of liver cirrhosis or hepatocellular cancer is delayed, but long-term administration is necessary and drug-resistant virus emerges causing recurrence
Solution Approach 1:
The patent divides the treatment approach into two distinct mechanisms: (1) nucleotide/nucleoside analogs that inhibit HBV DNA polymerase for viral load reduction, and (2) MAPK kinase inhibitors that block the MAPK signaling pathway to prevent viral recurrence and resistance. This segmented approach allows each agent to target different stages of HBV pathogenesis.
Solution Approach 2:
The patent employs a composite therapeutic strategy combining two different classes of compounds (nucleotide/nucleoside analogs and MAPK kinase inhibitors) with distinct modes of action. This composite approach synergistically addresses both viral suppression and prevention of drug resistance, similar to how composite materials combine different properties to achieve superior performance.
2Measurement precision
If existing HBV evaluation systems use infectious virus and limited cell types, then HBV infection and replication can be analyzed, but throughput is low, safety problems occur, and handling large quantities of samples is difficult
Solution Approach 1:
The patent creates a simplified copy of the HBV replication system using plasmid DNA containing HBV genomic sequences instead of infectious virus particles. This copy maintains the essential replication mechanisms while eliminating safety hazards and enabling high-throughput processing of multiple samples simultaneously.
Solution Approach 2:
The patent develops a universal evaluation system using common cell lines (HEK293T, HEK293, HeLa) that can evaluate HBV replication without requiring specialized cell types or infectious virus. This universal system handles diverse samples including plasma, serum, and cultured cells, making it adaptable to various research and clinical needs.
3Adaptability or versatility
If cells overexpressing NTCP are used for HBV infection experiments, then receptor-mediated infection can be studied, but infection efficiency is very low and culturing requires long periods of time
Solution Approach 1:
The patent extracts the essential elements of HBV replication (genomic DNA sequences, polymerase function) from the complex infectious virus particle and NTCP-dependent entry process. By focusing on plasmid-based DNA replication in transfected cells, the system eliminates the bottleneck of low-efficiency receptor-mediated infection while preserving the ability to study replication mechanisms.
Data Source
AI summary
An evaluation system for replication activity of HBV capable of visualizing and quantifying replication of HBV DNA in a short period of time inexpensively, safely, and rapidly and a method for evaluation using the system are developed and provided. Moreover, a novel composition for inhibiting HBV replication with a mode of action different from that of conventional anti-HBV drugs is developed and provided. A therapeutic agent for hepatitis B comprising as an active ingredient an HBV-Pol activity inhibitor consisting of a phosphorylation inhibitor that inhibits phosphorylation of a TxY motif present in Terminal protein region of HBV-Pol is provided.